Behcet Syndrome Clinical Trial
Official title:
Phase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's Disease
The purpose of this study is to determine the safety and efficacy of natural human interferon alpha (IFN alpha) on size, number, incidence and pain of oral ulcers associated with Behçet's Disease (BD).
Status | Completed |
Enrollment | 84 |
Est. completion date | April 2008 |
Est. primary completion date | April 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Is a male or a non-pregnant, non-lactating female. - Has a history and clinical presentation consistent with a diagnosis of Behçet's Disease and meets International Study Group criteria (Appendix B). - Has a history of oral ulcers for at least 12 months. - Has a history of monthly episodes of multiple oral ulcers. - Has the presence of at least 2 oral ulcers at study entry, both of which are accessible to measurement, with a total diameter of at least 4 mm. - Has signed an IRB approved subject consent form. - Has completed all screening procedures satisfactorily, is deemed to be an acceptable subject and is otherwise eligible for entry into the study. - Is willing and able to comply with the protocol. Exclusion Criteria: - Has a severe, acute, or chronic systemic disease other than Behçet's Disease such as congestive heart failure, hepatic failure, renal failure, Systemic Lupus Erythematosus (SLE), Stevens-Johnson syndrome, ulcerative colitis, cancer, leukemia, diabetes, AIDS or ARC, or any other condition for which they are immunocompromised. - Is under active treatment for dental conditions, such that multiple dental office visits would be required during the study period, or presents with oral conditions which are not thought to be related to Behçet's Disease and, in the judgment of a qualified dentist, will require treatment during the study period. - Is suffering from any medical condition other than Behçet's Disease known to cause oral ulcerations, such as erosive lichen planus, benign mucous membrane pemphigoid, SLE, Crohn's disease, Reiter's syndrome, or AIDS. - Has an eating disorder and/or psychiatric illness requiring treatment. - Has hypersensitivity to interferon-alpha. - Is a pregnant or lactating female, or is of childbearing potential and is not using a medically acceptable contraceptive method throughout the study. - Has had previous exposure to any parenteral interferon therapy. - Has had exposure to IFNa lozenges within 30 days of screening. - Has had exposure to thalidomide within 30 days of screening. - Has had exposure to methotrexate within 30 days of screening. - Has had exposure to any immune-suppressive medication within 30 days of screening. - Has a history of, or is currently exhibiting, any disease or condition which, in the opinion of the Principal Investigator, would place the subject at increased risk during study therapy. - Has any abnormality in a hematological or biochemical variable which, in the opinion of the Principal Investigator, would place the subject at increased risk during study therapy. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Turkey | Gulhane Military Medical School | Ankara | |
Turkey | Osmangazi University Medical School, Dept of Rheumatology | Eskisehir | |
Turkey | Istanbul University Cerrahpasa Medical School Department of Internal Medicine | Istanbul | |
Turkey | Istanbul University Istanbul Medical School | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Nobel Pharmaceuticals | Amarillo Biosciences, Inc. |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of Patients Experiencing a Sustained Response for Each Treatment Arm. | (0-12 weeks) | No | |
Secondary | Time to Initial Response, Oral Ulcer Sustained Response, Oral Ulcer Recurrence, Time to Recurrence, Pain Associated With Oral Lesions, General Well-Being, Safety | 12 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03274648 -
Dietary Interventions and Butyrate Production in Behçet's Patients
|
N/A | |
Terminated |
NCT01693653 -
Tocilizumab for the Treatment of Behcet's Syndrome
|
Phase 2 | |
Completed |
NCT04961463 -
Evaluation of the Psychoeducation Program Given to Behcet's Patients in the Context of the Roy Adaptation Model
|
N/A | |
Completed |
NCT05142995 -
Sleep Related Breathing Disorders, Anxiety, Depression and Quality of Life Assessment in Behcet's Disease
|
||
Recruiting |
NCT00931957 -
Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease
|
N/A | |
Completed |
NCT03514056 -
Frequency of Fibromyalgia in Behcet Disease
|
||
Not yet recruiting |
NCT03771768 -
Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease
|
N/A | |
Terminated |
NCT03554161 -
Tocilizumab for the Treatment of Refractory Behcet's Uveitis
|
Phase 2 | |
Recruiting |
NCT04738864 -
Neuro-ultrasound Assessment in Behcet's Disease
|
N/A | |
Completed |
NCT03264391 -
Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography
|
||
Completed |
NCT04386824 -
Erectile Dysfunction in Patients With Non Ocular Behçet's Disease
|
||
Completed |
NCT03962335 -
Gut Microbiota and Behcet's Syndrome: a Dietary Intervention Trial (MAMBA Study)
|
N/A | |
Completed |
NCT01532570 -
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
|
Phase 3 | |
Not yet recruiting |
NCT04186559 -
Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers
|
Phase 2 | |
Terminated |
NCT04218565 -
Golimumab for the Treatment of Refractory Behcet's Uveitis
|
Phase 2 | |
Not yet recruiting |
NCT03747354 -
Assessment of Disease Activity in Behcet by Complete Blood Count
|
N/A | |
Recruiting |
NCT05200715 -
AutoInflammatory Disease Alliance Registry (AIDA)
|
||
Completed |
NCT05098678 -
Zinc Supplementation and Behçet's Syndrome
|
N/A | |
Completed |
NCT00866359 -
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease
|
Phase 2 | |
Completed |
NCT05032248 -
Uses of Tacrolimus in Behcet Disease
|
N/A |